Whitehawk Therapeutics Inc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Lennon
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Headquarters Plaza Morristown NJ United States of America 07960
- IPO Date
- Aug 1, 2017
- CIK
- 0001422142
- Website
- ir.whitehawktx.com
- Similar Companies
- Business
- Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for difficult-to-treat cancers. Incorporated in 2007 and headquartered in Morristown, New Jersey, the company offers a three-asset ADC portfolio engineered with advanced next-generation platform technology featuring highly stable cleavable linkers and topoisomerase I inhibitor payloads; these assets target clinically validated proteins such as MUC16, SEZ6, and PTK7 that are broadly expressed in high-need tumor types including non-small cell lung, small cell lung, and ovarian cancers. The portfolio, in-licensed exclusively from WuXi Biologics, emphasizes improved therapeutic index, stability, and minimal off-target toxicity compared to first-generation ADCs, with an initial development focus on lung and gynecological indications and plans to advance all three to IND within 15 months. In March 2025, the company rebranded from Aadi Bioscience Inc, completed the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $102.4 million in cash, and secured $100 million in PIPE financing to fund ADC development and operations into 2028. These strategic moves support upcoming clinical data readouts and pipeline progression through early clinical milestones.
Company News
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting